Skip to main content
Equibles
ZURA logo

ZURA · Zura Bio Ltd

Track ZURA — free

Use ZURA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.23 +0.35 (+5.95%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$597.02M
Shares
95.83M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.23 Open$5.80 Day$5.63–6.26 52W close$1.90–7.04 Avg vol 30d1.3M Short int11.4M · 11.9% float · 12.9d Short vol55% DataMar 2023–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$85.74M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$205.13M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+34.5%
Year over year · more shares
Price change (1Y)
+201.0%
Trailing year
Short interest
11.9%
Latest settlement · 12.9 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +19%
above
Price vs 50-day avg +12%
above
RSI (14) 61
neutral
MACD trend Negative
52-week position 84%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +4%
trailing
6-month return −1%
trailing
YTD return +19%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.94% of float · ▲ +8.8% MoM · 12.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
97 holders — near 3-yr high, broad support
Squeeze score 72
high risk · 0–100
Fundamentals
Poor
EPS growth −77%
Y/Y
Free cash flow $-64.9M
Quant / Vol
risk profile
Very High
Volatility 96%
annualized · 1-yr
Max drawdown −52%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+19% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
61 Neutral
MACD trend
Negative Bearish
52-week position
84% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.94% of float · ▲ +8.8% MoM · 12.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
97 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $6 · 84% Range high $7
vs 200-day avg +19% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZURA
Zura Bio Ltd
this stock
$597.02M +18.9% — — 11.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.42B +20.5% +46.2% 31.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.22B +7.2% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $64.25B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $60.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
97
% held
76.3%
Net QoQ
+6.7M sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
11
View
Short & Settlement
Short Interest Rising
Shares short
11.4M
Days to cover
12.9d
Change
+927.5K sh
View
Short Volume
Short vol %
55%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
4
Value
$23
As of
Aug 5, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-68.7M
EPS diluted
$-1.06
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 17, 2026
This year
21
View
Proposed Sales
Value
$287.7K
Shares
50.0K
Filed
Aug 18, 2026
View
Exempt Offerings
Offering
$112.5M
Filed
May 6, 2024
View

Performance

5D 20D 120D MTD YTD
ZURA +8.9% +4.4% -0.8% +12.5% +18.9%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY +8.8% +4.8% -15.9% +12.0% +6.0%
Key facts CIK 1855644 CUSIP G9TY5A101 13F (30d) 81 filings 81 filers Visit website Investor relations